Dr. Megan McGill is a physician-scientist working in biotech. She is currently the VP of Strategy and Transactions at BridgeBio, a biopharmaceutical company focused on creating medicines for patients with genetic diseases and cancers with clear genetic drivers.

Megan received a BA, magna cum laude, from the University of Pennsylvania in neuroscience, chemistry and music. She completed her MD and PhD degrees at New York University with a PhD in neuroimaging and MRI physics, and was elected to Alpha Omega Alpha Honor Medical Society. Megan trained as a radiologist at NYU Langone Medical Center and previously held roles at McKinsey & Co. in the firm's healthcare practice and Regenxbio, a gene therapy company. She is a founding member and co-chair of the International Crisis Group's Women's Alliance for Peace and sits on the board of the Harmony Program.